Pembrolizumab Plus Y90 Radioembolization in HCC Subjects
Status:
Active, not recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label multi-center trial designed to evaluate the efficacy as well as the
safety of combining pembrolizumab with Yttrium-90 (Y90) radioembolization in subjects with
poor prognosis (high risk) HCC not eligible for liver transplant or surgical resection with
well compensated liver function. Treatment will consist of pembrolizumab 200mg IV every 3
weeks in conjunction with Y90 radioembolization performed one week after the first dose of
pembrolizumab. If bilobar disease is present, a second Y90 radioembolization will be
performed no later than 4 weeks after the first procedure to the contralateral hepatic lobe.
Phase:
Early Phase 1
Details
Lead Sponsor:
Autumn McRee, MD Hoosier Cancer Research Network
Collaborators:
Hoosier Cancer Research Network Merck Sharp & Dohme Corp.